NGM-621

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameNGM-621
Drug Alias NameNGM-621
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionComplement C3 inhibitors
TargetsComplement C3
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Geographic Atrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNGM Biopharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesMerck & CoNGM Biopharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsGeographic Atrophy
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A